Phaseline

Companies › Lallemand Pharma

Lallemand Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Infectious disease; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Bacterial Lysates (PMBL®, ISMIGEN®)
Polyvalent mechanical bacterial lysate - stimulates innate and adaptive immune responses t
–Phase 4Respiratory Tract Infections (RTI)Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07578012Bacterial Lysates (PMBL®, ISMIGEN®)Phase 4Respiratory Tract Infections (RTI)Infectious diseaseMar 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Laboratorio Farmaceutico SIT srl Zero Point Five Therapeutics Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) MicuRx Jiangxi Qingfeng Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.